



Archived at the Flinders Academic Commons:

<http://dspace.flinders.edu.au/dspace/>

This is a copy of an article published in the *Journal of Palliative Medicine*, and is available online at:

<http://online.liebertpub.com/doi/full/10.1089/jpm.2011.0323>

Please cite this as: Hardy, J., Agar, M.R. and Currow, D.C., 2011. Progressing an evidence-base beyond case series. *Journal of Palliative Medicine*, 14(12), 1283.

DOI: <http://dx.doi.org/10.1089/jpm.2011.0323>

© 2011 Mary Ann Liebert, Inc. Paper reproduced here with permission from the publisher.

Progressing an Evidence-Base Beyond Case Series

Janet Hardy, B.Sc., MBChB, M.D., FRACP¹, Meera R. Agar, M.P.C., FRACP,^{2,3}
and David C. Currow, B.Med., M.P.H., FRACP³

Dear Editor:

We read with interest in the latest edition of this journal the four case reports reporting dramatic responses to sub-anaesthetic doses of ketamine in patients with complex pain syndromes poorly responsive to escalating doses of opioids.¹

The management of complex pain such as this remains challenging and at times most clinicians struggle with cases such as these. Treatment plans in these situations tend to be guided by physician experience and local practice and therefore vary greatly between centres as there is often little quality evidence to guide practice decisions.

Although it is of great interest to read of cases such as these, there is a concern that the experience presented by the publication of case reports cannot be used as an "evidence base" to guide future management. Instead, it should be used as a basis for properly blinded prospective studies.

Placebo response rates as high as 75% have been reported in chronic pain studies.² This may be because of patient expectation of benefit, a reflection of the extra care and attention given to patients on trials or the fact that patients are generally put on new treatments when their pain is at its worst and a number will improve over time to a baseline level without treatment. Significant placebo response rates should always be anticipated and considered when initiating any new analgesic intervention.

It is well documented that uncontrolled trials may greatly vary from subsequent point estimates in controlled studies often with over estimates of effect³ especially if it is not a consecutive series of cases that is presented. Conversely, case series of people given ketamine who experience negative outcomes are unlikely to be written or published.

Randomized trials are also needed for a true estimate of adverse effects. The authors of this case series note few "serious effects," yet report in two patients acute confusion (presumed delirium), somnolence, and psychomimetic effects. The other two patients were proactively treated with benzodiazepines that may have masked toxicity and equally was associated with toxicity in themselves. In case series it is less easy to standardize prior treatment such as opioids or adjuvants.

High-quality randomized trials in hospice and palliative care are achievable⁴ to provide quality evidence to guide our practice especially if several sites work together to conduct the trial.⁵ Palliative medicine is a specialty that is contributing more and more to the care of patients with life limiting disease. It is time we based this practice on high-quality evidence and that can only come with high-quality research.

References

1. Kerr C, Holahan T, Milch R; The use of ketamine in severe cases of refractory pain syndromes in the palliative care setting: a case series. *J Palliat Med* 2011;14:1-4.
2. McQuay H: Antidepressants and chronic pain. *Br Med J* 1997;314:763-764.
3. Kunz R, Oxman AD: The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. *BMJ* 1998;317:1185-1190.
4. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, Marcello J, Young IH, Bull J, Wilcock A, Booth S, Wheeler JL, Tulskey JA, Crockett AJ, Currow DC: Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: A double-blind randomized controlled trial (NCT00327873). *Lancet* 2010;376:784-793.
5. Currow DC, Shelby-James TM, Agar M, Plummer J, Rowett D, Glare P, Spruyt O, Hardy J: Planning phase III multi-site clinical trials in palliative care: The role of consecutive cohort audits to identify potential participant populations. *J Support Care Cancer* 2010;18:1571-1578.

Address correspondence to:
David C. Currow, B.Med., M.P.H., FRACP
Discipline, Palliative, and Supportive Services
Flinders University
700 Goodwood Road
Daw Park South Australia 5041
Australia

E-mail: david.currow@flinders.edu.au

¹Mater Health Services, Department of Palliative Care Queensland, Australia.

²Department of Palliative Care, Braeside Hospital, Prairiewood, New South Wales, Australia.

³Discipline, Palliative and Supportive Services, Flinders University, Adelaide, Australia.

This article has been cited by:

1. Brian H. Le, Mark A. Rosenthal. 2012. Redefining the Specialist Palliative Approach: Clinical Trials, a First Year Experience. *Journal of Palliative Medicine* **15**:8, 846-846. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2. David MacKintosh, Angela Brady, Sally Carr. 2012. Ketamine: A Real-World Experience in Cancer Pain. *Journal of Palliative Medicine* **15**:7, 733-733. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]